The Anti-inflammatory Effect of GV1001 Mediated by the Downregulation of ENO1-induced Pro-inflammatory Cytokine Production
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
GV1001 is a peptide derived from the human telomerase reverse transcriptase (hTERT) sequence that is reported to have anti-cancer and anti-inflammatory effects. Enolase1 (ENO1) is a glycolytic enzyme, and stimulation of this enzyme induces high levels of pro-inflammatory cytokines from concanavalin A (Con A)-activated peripheral blood mononuclear cells (PBMCs) and ENO1-expressing monocytes in healthy subjects, as well as from macrophages in rheumatoid arthritis (RA) patients. Therefore, this study investigated whether GV1001 downregulates ENO1-induced pro-inflammatory cytokines as an anti-inflammatory peptide. The results showed that GV1001 does not affect the expression of ENO1 in either Con A-activated PBMCs or RA PBMCs. However, ENO1 stimulation increased the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, and these cytokines were downregulated by pretreatment with GV1001. Moreover, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB were activated when ENO1, on the surface of Con A-activated PBMCs and RA PBMCs, was stimulated, and they were successfully suppressed by pre-treatment with GV1001. These results suggest that GV1001 may be an effective anti- inflammatory peptide that downregulates the production of pro-inflammatory cytokines through the suppression of p38 MAPK and NF-κB activation following ENO1 stimulation.
Abstract
GV1001 is a peptide derived from the human telomerase reverse transcriptase (hTERT) sequence that is reported to have anti-cancer and anti-inflammatory effects. Enolase1 (ENO1) is a glycolytic enzyme, and stimulation of this enzyme induces high levels of pro-inflammatory cytokines from concanavalin A (Con A)-activated peripheral blood mononuclear cells (PBMCs) and ENO1-expressing monocytes in healthy subjects, as well as from macrophages in rheumatoid arthritis (RA) patients. Therefore, this study investigated whether GV1001 downregulates ENO1-induced pro-inflammatory cytokines as an anti-inflammatory peptide. The results showed that GV1001 does not affect the expression of ENO1 in either Con A-activated PBMCs or RA PBMCs. However, ENO1 stimulation increased the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, and these cytokines were downregulated by pretreatment with GV1001. Moreover, p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB were activated when ENO1, on the surface of Con A-activated PBMCs and RA PBMCs, was stimulated, and they were successfully suppressed by pre-treatment with GV1001. These results suggest that GV1001 may be an effective anti- inflammatory peptide that downregulates the production of pro-inflammatory cytokines through the suppression of p38 MAPK and NF-κB activation following ENO1 stimulation.
참고문헌 (43)
- Middleton, G., "Gemcitabine capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac):an open-label, randomised, phase 3 trial", Lancet Oncol, 15, pp.829~840 (2014)
- Staff, C., "Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients", Int. J. Oncol, 45, pp.1293~1303 (2014)
- Annels, N. E., "The effects of gemcitabine capecitabine combination chemotherapy of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer", Cancer Immunol. Immunother, 63, pp.175~183 (2014)
- Brunsvig, P. F., "Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy an 8-year update on a phase I", II trial, 2011, pp.17, 6847~6857
- Hunger, R. E., "Vaccination of patients with cutaneous melanoma with telomerase-specific peptides", Cancer Immunol. Immunother, 60, pp.1553~1564 (2011)
- Lee, S. A., "Heat shock protein-mediated cell penetration cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine", Biomaterials, 34, pp.7495~7505 (2013)
- Koo, T. Y., "Protective effect of peptide GV1001 against renal ischemia-reperfusion injury in mice", Transplant. Proc, 46, pp.1117~1122 (2014)
- Greten, T. F., "A phase II open label trial evaluating safety efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma", BMC Cancer, 10, pp.209~ (2010)
- Miles, L. A., "Role of cell-surface lysines in plasminogen binding to cells : identification of alpha-enolase as a candidate plasminogen receptor", Biochemistry, 30, pp.1682~1691 (1991)
- Redlitz, A., "The role of an enolase-related molecule in plasminogen binding to cells", Eur. J. Biochem, 227, pp.407~415 (1995)
- Lopez-Alemany, R., "Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase", Am. J. Hematol, 72, pp.234~242 (2003)
- Wygrecka, M., "Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung", Blood, 113, pp.5588~5598 (2009)
- Giallongo, A., "Isolation partial characterization of a 48-kDa protein which is induced in normal lymphocytes upon mitogenic stimulation", Biochem. Biophys. Res. Commun, 134, pp.1238~1244 (1986)
- Felez, J., "Regulation of plasminogen receptor expression on human monocytes monocytoid cell lines", J. Cell Biol, 111, pp.1673~1683 (1990)
- Bae, S., "alpha-Enolase expressed on the surfaces of monocytes macrophages induces robust synovial inflammation in rheumatoid arthritis", J. Immunol, 189, pp.365~372 (2012)
- Saulot, V., "Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis", Arthritis Rheum, 46, pp.1196~1201 (2002)
- Mosca, M., "Prevalence clinico-serological correlations of anti-alpha-enolase, anti-C1q, antidsDNA antibodies in patients with systemic lupus erythematosus", J. Rheumatol, 33, pp.695~697 (2006)
- Wakui, H., "Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN)", Clin. Exp. Immunol, 118, pp.445~450 (1999)
- Sweeney, S. E., "Rheumatoid arthritis:regulation of synovial inflammation", Int. J. Biochem. Cell Biol, 36, pp.372~378 (2004)
- Tak, P. P., "Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis", Arthritis Rheum, 38, pp.1457~1465 (1995)
- Ishikawa, H., "An immunohistochemical immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis", Rheumatol. Int, 16, pp.53~60 (1996)
- Furuzawa-Carballeda, J., "Osteoarthritis rheumatoid arthritis pannus have similar qualitative metabolic characteristics pro-inflammatory cytokine response", Clin. Exp. Rheumatol, 26, pp.554~560 (2008)
- Xue, C., "Characterisation of fibroblast-like cells in pannus lesions of patients with rheumatoid arthritis sharing properties of fibroblasts chondrocytes", Ann. Rheum. Dis, 56, pp.262~267 (1997)
- Robinson, D. R., "Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis", J. Clin. Invest, 56, pp.1181~1188 (1975)
- Kotake, S., "Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients", Arthritis Rheum, 44, pp.1003~1012 (2001)
- Van Boxel, J. A., "Predominantly T-cell infiltrate in rheumatoid synovial membranes", N. Engl. J. Med, 293, pp.517~520 (1975)
- Slauenwhite, D., "Regulation of cytokine polarization T cell recruitment to inflamed paws in mouse collagen-induced arthritis by the chemokine receptor CXCR6", Arthritis Rheumatol, 66, pp.3001~3012 (2014)
- Brennan, F., "Update on cytokines in rheumatoid arthritis", Curr. Opin. Rheumatol, 19, pp.296~301 (2007)
- Firestein, G. S., "Starving the synovium: angiogenesis inflammation in rheumatoid arthritis", J. Clin. Invest, 103, pp.3~4 (1999)
- Moore, T. L., "Measurement evaluation of isotypes of anti-citrullinated fibrinogen anti-citrullinated alpha-enolase antibodies in juvenile idiopathic arthritis", Clin. Exp. Rheumatol, 32, pp.740~746 (2014)
- Myasoedova, E., "Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007", Arthritis Rheum, 62, pp.1576~1582 (2007)
- Miossec, P., "An update on the cytokine network in rheumatoid arthritis", Curr. Opin. Rheumatol, 16, pp.218~222 (2004)
- Matsukawa, A., "Analysis of the inflammatory cytokine network among TNF alpha, IL-1 beta, IL-1 receptor antagonist, IL-8 in LPS-induced rabbit arthritis", Lab. Invest, 76, pp.629~638 (1997)
- McInnes, I. B., "Cytokines in the pathogenesis of rheumatoid arthritis", Nat. Rev. Immunol, 7, pp.429~442 (2007)
- Jue, D. M., "Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis", J. Korean Med. Sci, 14, pp.231~238 (1999)
- Ivashkiv, L. B., "The JAK", STAT pathway in rheumatoid arthritis: pathogenic or protective?, 2003, pp.48, 2092~2096
- Isomaki, P., "The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels", Rheumatology, 54, pp.1103~1113 (2015)
- Campbell, L., "Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review meta-analysis of randomized controlled trials", Rheumatology, 50, pp.552~562 (2011)
- Nishimoto, N., "Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp", Pharmacol, pp.151~160 (2008)
- Cohen, G., "The efficiency of switching from infliximab to etanercept vice-versa in patients with rheumatoid arthritis", Clin. Exp. Rheumatol, 23, pp.795~800 (2005)
- Makarov, S. S., "NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, tissue destruction", Arthritis Res, 3, pp.200~206 (2001)
- Simmonds, R. E., "Signalling, inflammation arthritis: NF-kappaB its relevance to arthritis inflammation", Rheumatology, 47, pp.584~590 (2008)
- Clark, A. R., "The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look", Open Rheumatol. J, 6, pp.209~219 (2012)